Clinically Proven Human Milk Probiotic LC40 supports Infant Health and Breastfeeding Mothers
SINGAPORE, Sept. 15, 2025 /PRNewswire/ -- Supported by six clinical studies and two…
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented…
Angelalign Technology Denies Patent Infringement and Vows Vigorous Defense
SAN CLEMENTE, Calif., Aug. 20, 2025 /PRNewswire/ -- Angelalign Technology Inc. (6699.HK) ("Angel") categorically denies…
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
EyeCare Partners Releases Inaugural Quality and Outcomes Report, Showcasing Impact and Industry-Leading Benchmarks
ST. LOUIS--(BUSINESS WIRE)--EyeCare Partners (ECP), the nation’s leading provider of clinically integrated…